Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy

Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Blood (Impact Factor: 9.78). 04/2005; 105(7):2793-801. DOI: 10.1182/blood-2003-05-1433
Source: PubMed

ABSTRACT Cell-mediated immunity is essential for control of human cytomegalovirus (HCMV) infection. We used a pool of 138 synthetic overlapping pentadecapeptides overspanning the entire pp65 protein to generate polyclonal CMV-specific T-cell lines from 12 CMV-seropositive donors inheriting different HLA genotypes. Autologous monocyte-derived dendritic cells (DCs) pulsed with this complete pool consistently induced highly specific T cells that selectively recognized 1-3 pentadecapeptides identified by secondary responses to a mapping grid of pentadecapeptide subpools with single overlaps. Responses against peptide-loaded targets sharing single HLA class I or II alleles identified the restricting HLA alleles. HLA-A*0201+ donors consistently responded to pentadecapeptides containing HLA-A*0201-binding epitope(aa495-503)NLVPMVATV. T-cell lines from other donors contained high frequencies of CD4 and/or CD8 T cells selectively reactive against peptides presented by other HLA alleles, including both known epitopes such as (aa341-350)QYDPVAALF (HLA-A*2402) as well as unreported epitopes such as (aa267-275)HERNGFTVL (HLA-B*4001 and B*4002) and (aa513-523)FFWDANDIYRI (HLA-DRB1*1301). These T cells consistently lysed CMV-infected target cells. Thus, this approach fosters expansion and selection of HLA-restricted CMV-pp65-reactive T-cell lines of high specificity that also lyse CMV-infected targets, and from a functional and regulatory perspective, may have advantages for generating virus-specific T cells for adoptive immunotherapy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Although allogeneic hematopoietic stem-cell transplantation (HSCT) is a curative approach for many pediatric patients with hematologic malignancies and some non-malignant disorders, there are still critical obstacles to overcome including relapse, engraftment failure, graft-versus-host disease (GvHD) and infection. Harnessing the immune system to induce a graft-versus-tumor (GvT) effect or rapidly restore anti-viral immunity through the use of donor lymphocyte infusion (DLI) has been remarkably successful in some settings. Unfortunately, the responses to DLI can be variable and GVHD is common. Hence, manipulations to minimize GVHD while restoring antiviral immunity and enhancing GvT are necessary to improve outcomes after allogeneic HSCT. Cellular therapies are defined as treatment modalities in which hematopoietic or non-hematopoietic cells are used as therapeutic agents and offer this promise to improve outcomes post HSCT. This review will present an overview of the field for pediatric cell therapies in the transplant setting and discuss how we can broaden applicability beyond phase I.
    Biology of Blood and Marrow Transplantation 07/2014; 21(3). DOI:10.1016/j.bbmt.2014.07.018 · 3.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Viral infections remain a major cause of morbidity in patients with immunodeficiency, such as recipients of hemopoietic stem cell transplantation. Adoptive transfer of donor-derived virus-specific cytotoxic T lymphocytes is a strategy to restore virus-specific immunity to prevent or treat viral diseases and has been tested in the clinical setting for more than 20 years. Several different groups have used expanded virus-specific T-cell products specific for one or multiple viruses to both reconstitute antiviral immunity after transplantation and to treat active viral infections. Response rates are encouraging, although resistance has been seen when the infused cell population has had restricted specificity or has targeted antigens expressed in donor-infected but not virally infected recipient cells. The goal of current trials is to make this approach more broadly applicable using more rapidly available products from the donor, such as directly selected or briefly expanded cells or closely matched banked cells.
    Hematology 12/2013; 2013:342-7. DOI:10.1182/asheducation-2013.1.342 · 2.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cytomegalovirus (CMV) reactivation after stem cell transplantation can be treated with CMV-specific T cells, but current in vitro techniques using dendritic cells as antigen-presenting cells are time-consuming and expensive. To simplify the production of clinical grade CMV-specific T cells, we evaluated gene-modified activated T cells [antigen presenting T cells (T-APCs)] as a reliable and easily produced source of APCs to boost CD4+ and CD8+ T-cell responses against the immunodominant CMV antigen pp65. T-APCs expressing the full-length immunodominant CMV pp65 gene were used to stimulate the expansion of autologous T cells. After 10 to 14 days, the T cell lines were tested for antigen specificity by using the flow cytometric intracellular detection of interferon-gamma after stimulation for 6 hours with a pp65 peptide library of 15-mers, overlapping by 11 amino acids. Under optimal conditions, this technique induced a median 766-fold and a 652-fold expansion of pp65-specific CD4+ and CD8+ responder cells, respectively, in 15 T cell lines. In 13 of 15 T cell lines, over 10 antigen-specific CD4+ plus CD8+ T cells were generated starting with only 5x10 peripheral blood mononuclear cells, representing an over 3-log increase. These data indicate that T-APCs efficiently boost pp65-specific CD4+ and CD8+ T cell numbers to clinically useful levels. The approach has the advantage of using a single leukocyte collection from the donor to generate large numbers of CMV-specific T cells within a total 3-week culture period using only one stimulation of antigen.
    Journla of Immunotherapy 01/2006; 29(4):436-43; discussion 365-6. DOI:10.1097/01.cji.0000211302.52503.93 · 3.35 Impact Factor


Similar Publications